GleamWall
中文EN

MDGL MADRIGAL PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1157601 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY92.8%
TTM net income YoY46.2%
TTM EPS YoY24.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-10.7%
Net margin-10.9%
FCF margin-11.8%
EBITDA margin-10.6%

Returns

ROE-24.8%
ROA-11.1%
ROIC (approx.)-21.6%
Asset turnover1.02x

Leverage & solvency

Liabilities / assets56.3%
Debt / equity0.54x
Current ratio3.05x
Interest coverage-4.75x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$431.27M$364.25M$311.34M$321.08M$287.27M$212.80M$137.25M$103.32M
Cost of revenue——————$4.51M—
Gross profit——————$132.74M—
R&D expense$71.75M$91.18M$108.69M$116.27M$174.00M$54.08M$44.17M$25.65M
SG&A expense$265.71M$289.38M$268.52M$239.98M$209.12M$196.86M$167.88M$141.22M
Operating income$55.99M-$56.31M-$92.72M-$59.61M-$113.97M-$47.20M-$79.31M-$67.00M
Interest expense$8.07M$7.94M$7.82M$8.30M$7.45M$3.26M$3.30M$3.50M
Net income$55.44M-$57.94M-$94.39M-$58.58M-$114.19M-$42.28M-$73.24M-$59.42M
EBITDA$56.38M-$55.93M-$92.34M-$59.22M-$113.62M-$46.83M-$78.93M-$66.63M
EPS (basic)1.90-1.99-3.25—-4.01-1.50-2.61—
EPS (diluted)1.83-1.99-3.25—-4.01-1.50-2.61—
Weighted avg. shares (diluted)30.31M29.15M29.03M—28.51M28.23M28.09M—
Balance sheet
Cash & equivalents$514.64M$292.73M$227.03M$198.69M$300.69M$191.19M$188.65M$105.02M
Short-term investments$446.32M$546.03M$585.74M$784.87M$814.05M$610.83M$659.42M$826.23M
Receivables$227.38M$192.31M$187.36M$134.48M$113.28M$79.23M$61.43M$53.82M
Inventory$122.59M$99.39M$112.07M$74.84M$69.32M$63.50M$55.24M$34.07M
Current assets$1.39B$1.20B$1.18B$1.25B$1.35B$1.00B$987.98M$1.03B
PP&E, net$13.96M$11.59M$8.04M$1.50M$2.91M$1.61M$1.90M$2.19M
Intangibles$7.09M$7.19M$7.28M$7.38M$7.48M$4.55M$4.64M$4.73M
Total assets$1.43B$1.24B$1.23B$1.26B$1.36B$1.02B$996.63M$1.04B
Current liabilities$454.24M$374.20M$338.26M$310.29M$391.41M$196.50M$167.24M$169.28M
Long-term debt$341.27M$340.79M$340.33M$339.88M$339.75M$118.38M$118.00M$117.57M
Total debt$341.27M$340.79M$340.33M$339.88M$339.75M$118.38M$118.00M$117.57M
Total liabilities$807.45M$720.92M$683.87M$656.90M$736.73M$319.40M$285.99M$287.86M
Shareholders' equity$626.94M$523.72M$543.45M$602.69M$625.73M$695.98M$710.64M$754.38M
Net debt-$173.37M$48.07M$113.30M$141.19M$39.06M-$72.82M-$70.64M$12.55M
Shares outstanding23.22M23.09M23.04M22.84M22.70M22.22M22.19M22.00M
Cash flow statement
Operating cash flow$120.56M$23.33M-$167.44M-$133.46M$79.85M-$47.05M-$88.89M-$104.49M
Capital expenditure$3.93M$4.25M$3.85M-$390,000$857,000$0$0$195,000
Free cash flow$116.63M$19.08M-$171.28M-$133.07M$78.99M-$47.05M-$88.89M-$104.68M
Investing cash flow$93.79M$34.20M$192.19M$27.58M-$207.00M$47.86M$163.88M-$47.95M
Financing cash flow$9.96M$3.11M$2.33M$8.96M$236.65M$1.74M$8.64M$19.77M
Depreciation & amortization$391,000$381,000$386,000$392,000$358,000$377,000$379,000$363,000
Stock-based compensation$38.95M$35.37M$34.02M$25.79M$26.25M$25.16M$20.93M$17.68M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.